Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma

Oncology

Volumn 81, Issue 5-6, 2012, Pages 372-380

  Cheng, Ann Lii ^a,b   Shen, Ying Chun ^a   Zhu, Andrew X ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cirrhosis; Fibroblast growth factor receptor; Fibrosis; Hepatocellular carcinoma; Multikinase inhibitor

Indexed keywords

BRIVANIB; DOVITINIB; FIBROBLAST GROWTH FACTOR 17; FIBROBLAST GROWTH FACTOR 18; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 22; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 5; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR 9; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; NINTEDANIB; RABEPRAZOLE; SORAFENIB; UNCLASSIFIED DRUG;

CELL FUNCTION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84856065348     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000335472     Document Type: Review

References (48)

1. Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
2. National Comprehensive Cancer Network: NCCN Clinical practice guidelines in oncology. Hepatobiliary Cancers, version 1. 2011.
3. Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
4. Motoo Y, Sawabu N, Yamaguchi Y, Terada T, Nakanuma Y: Sinusoidal capillarization of human hepatocellular carcinoma: possible promotion by fibroblast growth factor. Oncology 1993; 50: 270-274. (Pubitemid 23193919)
5. Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J: Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 2001; 182: 298-304. (Pubitemid 32918381)
6. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW: Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol 2002; 160: 641-654. (Pubitemid 34160342)
7. Turner N, Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116-129.
8. Hughes SE: Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 1997; 45: 1005-1019. (Pubitemid 27284024)
9. Presta M, Maier JAM, Rusnati M, Ragnotti G: Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J Cell Physiol 1989; 140: 68-74. (Pubitemid 19180158)
10. Serls AE, Doherty S, Parvatiyar P, Wells JM, Deutsch GH: Different thresholds of fibroblast growth factors pattern the ventral foregut into liver and lung. Development 2005; 132: 35-47. (Pubitemid 40207965)
11. Werner S, Peters KG, Longaker MT, Fuller-Pace F, Banda MJ, Williams LT: Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc Natl Acad Sci USA 1992; 89: 6896-6900.
12. Desnoyers LR, Pai R, Ferrando RE, Hotzel K, Le T, Ross J, Carano R, D'Souza A, Qing J, Mohtashemi I, Ashkenazi A, French DM: Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 27: 85-97.
13. Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, Pham TA, Dillard-Telm L, Tsai SP, Stephan JP, Stinson J, Stewart T, French DM: A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 160: 2295-2307. (Pubitemid 34663420)
14. Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, Gupte J, Hager T, Wang Z, Lindberg R, Li Y: FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010; 285: 5165-5170.
15. Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L, Zhao A, Busuttil RW, Yee H, Stein L, French DM, Finn RS, Lowe SW, Powers S: Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 2011; 19: 347-358.
16. Mas VR, Maluf DG, Archer KJ, Yanek KC, Fisher RA: Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation 2007; 84: 1262-1271. (Pubitemid 351339314)
17. Harimoto N, Taguchi K, Shirabe K, Adachi E, Sakaguchi Y, Toh Y, Okamura T, Kayashima H, Taketomi A, Maehara Y: The significance of fibroblast growth factor receptor 2 expression in differentiation of hepatocellular carcinoma. Oncology 2010; 78: 361-368.
18. Qiu WH, Zhou BS, Chu PG, Chen WG, Chung C, Shih J, Hwu P, Yeh C, Lopez R, Yen Y: Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol 2005; 11: 5266-5272. (Pubitemid 41410290)
19. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A: Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009; 50: 118-127.
20. Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, Stattner S, Bichler C, Kandioler D, Wrba F, Schulte-Hermann R, Holzmann K, Grusch M, Marian B, Berger W, Grasl-Kraupp B: Upregulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology 2011; 53: 854-864.
21. Jin-no K, Tanimizu M, Hyodo I, Kurimoto F, Yamashita T: Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. J Gastroenterol 1997; 32: 119-121. (Pubitemid 27075893)
22. Kanda S, Tomasini-Johansson B, Klint P, Dixelius J, Rubin K, Claesson-Welsh L: Signaling via fibroblast growth factor receptor-1 is dependent on extracellular matrix in capillary endothelial cell differentiation. Exp Cell Res 1999; 248: 203-213. (Pubitemid 29393943)
23. Uematsu S, Higashi T, Nouso K, Kariyama K, Nakamura S, Suzuki M, Nakatsukasa H, Kobayashi Y, Hanafusa T, Tsuji T, Shiratori Y: Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005; 20: 583-588. (Pubitemid 40755271)
24. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. 2007; 11: 83-95.
25. Casanovas O, Hicklin DJ, Bergers G, Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in latestage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309. (Pubitemid 41443415)
26. Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005; 115: 209-218. (Pubitemid 40385459)
27. Gressner AM, Weiskirchen R: Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99. (Pubitemid 44874293)
28. Yu C, Wang F, Jin C, Huang X, Miller DL, Basilico C, McKeehan WL: Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am J Pathol 2003; 163: 1653-1662. (Pubitemid 37175112)
29. Antoine M, Wirz W, Tag CG, Gressner AM, Marvituna M, Wycislo M, Hellerbrand C, Kiefer P: Expression and function of fibroblast growth factor (FGF) 9 in hepatic stellate cells and its role in toxic liver injury. Biochem Biophys Res Commun 2007; 361: 335-341. (Pubitemid 47187264)
30. Yu C, Wang F, Jin C, Wu X, Chan W, Mc-Keehan WL: Increased carbon tetrachlorideinduced liver injury and fibrosis in FGFR4-deficient mice. Am J Pathol 2002; 161: 2003-2010. (Pubitemid 35434846)
31. Böhm F, Speicher T, Hellerbrand C, Dickson C, Partanen J, Ornitz D, Werner S: FGF receptors 1 and 2 control chemically-induced injury and compound detoxification in regenerating livers of mice. Gastroenterology 2010; 139: 1385-1396.
32. Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G, Pagliaro L: Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991; 36: 962-972.
33. Bhide RS, Lombardo LJ, Hunt JT, Cai Z, Barrish JC, Galbraith S, Jeyaseelan R, Mortillo S, Wautlet BS, Krishnan B: The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 2010; 9: 369-378.
34. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E: Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 6146-6153.
35. Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, Kollia G, Nuyten DS, Galbraith S: A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol 2011; 22: 1413-1419.
36. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas MB, Harris R, Baudelet C, Walters I, Raoul J: Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011; 17: 1973-1983.
37. Raoul JL, Finn RS, Kang YK, Park JW, Harris R, Coric V, Donica M, Walters I: An openlabel phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC) (abstract 4577). J Clin Oncol 2009; 27: 15s.
38. Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S, Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, de Bono JS: A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 2075-2081. (Pubitemid 351551118)
39. Kanai F, Yoshida H, Tateishi R, Sato S, Kawabe T, Obi S, Kondo Y, Taniguchi M, Tagawa K, Ikeda M, Morizane C, Okusaka T, Arioka H, Shiina S, Omata M: A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011; 67: 315-324.
40. Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, Strecker R, Henning J, Gaschler-Markefski B, Stopfer P, de Rossi L, Kaiser R: Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010; 16: 311-319.
41. Kudo K, Arao T, Tanaka K, Nagai T, Furuta K, Sakai K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, De Velasco MA, Fujita Y, Saijo N, Kudo M, Nishio K: Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo. Clin Cancer Res 2011; 17: 1373-1381.
42. Chaudhary NI, Roth GJ, Hilberg F, Müller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE: Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29: 976-985. (Pubitemid 46711904)
43. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kluglich M, du Bois RM: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087.
44. Bello E, Colella G, Scarlato V, Oliva P, Berndt A, Valbusa G, Serra SC, D'Incalci M, Cavalletti E, Giavazzi R: E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res 2011; 71: 1396-1405.
45. Soria J, De Braud FG, Cereda R, Bahleda R, Delmonte A, Angevin E, Varga A, Noberasco C, Dall'O' E, Lassau N, Dromain C, Bellomi M, Farace F, Bertolini F, Zucchetti M, Marsoni S, Camboni MG: First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors. J Clin Oncol 2011; 29(suppl):abstract TPS149.
46. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM: Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281: 15694-15700. (Pubitemid 43848456)
47. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JÖ, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacody namic relationship. Clin Cancer Res 2003; 9: 327-337. (Pubitemid 36109749)
48. Paz K, Zhu Z: Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2 for cancer therapy; in Bradbury RH (ed): Cancer. Top Med Chem. Berlin, Springer, 2007, vol 1, pp 333-382.